<DOC>
	<DOCNO>NCT00097760</DOCNO>
	<brief_summary>The purpose study determine natalizumab combination Glatiramer Acetate ( GA ) safe effective delay progression individual diagnose relapsing-remitting Multiple Sclerosis ( MS ) .</brief_summary>
	<brief_title>Natalizumab Combination With Glatiramer Acetate ( GA ) Patients With Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Diagnosis MS define McDonald et al. , criterion # 14 Between age 18 55 , inclusive Baseline EDSS score 0.0 5.0 , inclusive Have treat GA least 12 month prior randomization Primary progressive , secondary progressive progressive relapse MS MS relapse occur within 50 day prior randomization A clinically significant infectious illness History , abnormal lab result indicative significant disease would preclude administration recombinant humanize antibody immunomodulating agent GA 20 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
</DOC>